ArticleThe American journal of pathology2011
Identification of potential biomarkers for giant cell tumor of bone using comparative proteomics analysis.
Article in The American journal of pathology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 46 citations in OpenAlex.
- Significance of Biogenetic Markers in Giant Cell Tumor Differentiation and Prognosis: A Narrative Review.Diagnostics (Basel, Switzerland) · 2024Review
- Characteristics of Giant Cell Tumor of the Bone in Pediatric Patients: Our 18-Year, Single-Center Experience.Children (Basel, Switzerland) · 2021Article
- Exploring the Proteomic Alterations from Untreated and Cryoablation and Irradiation Treated Giant Cell Tumors of Bone Using Liquid-Chromatography Tandem Mass Spectrometry.Molecules (Basel, Switzerland) · 2020Article
- Observational
- Decreased Lung Tumor Development in SwAPP Mice through the Downregulation of CHI3L1 and STAT 3 Activity via the Upregulation of miRNA342-3p.Molecular therapy. Nucleic acids · 2019Article
- Prognosis of local recurrence in giant cell tumour of bone: what can we do?La Radiologia medica · 2017Review
- Presenilin Mutation Suppresses Lung Tumorigenesis via Inhibition of Peroxiredoxin 6 Activity and Expression.Theranostics · 2017Article
- Translational research in diagnosis and management of soft tissue tumours.Cancer imaging : the official publication of the International Cancer Imaging Society · 2016Review
- Biomarkers for Bone Tumors: Discovery from Genomics and Proteomics Studies and Their Challenges.Molecular medicine (Cambridge, Mass.) · 2016Article
- Article
- Aged monkey brains reveal the role of ubiquitin-conjugating enzyme UBE2N in the synaptosomal accumulation of mutant huntingtin.Human molecular genetics · 2015Article
- Tissue and serum IGFBP7 protein as biomarker in high-grade soft tissue sarcoma.American journal of cancer research · 2015Article
- Loss of presenilin 2 is associated with increased iPLA2 activity and lung tumor development.Oncogene · 2014Article
- Identification and validation of dysregulated metabolic pathways in metastatic renal cell carcinoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- UBE2Q1, as a Down Regulated Gene in Pediatric Acute Lymphoblastic Leukemia.International journal of molecular and cellular medicine · 2014Article
- Article
- Retrospective analysis of patients with rare-site and metastatic giant cell tumor.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2013Article
- p53 mutations may be involved in malignant transformation of giant cell tumor of bone through interaction with GPX1.Virchows Archiv : an international journal of pathology · 2013Article
- Modern interpretation of giant cell tumor of bone: predominantly osteoclastogenic stromal tumor.Clinics in orthopedic surgery · 2012Review
- Tartrate-Resistant Acid Phosphatase 5b is a Useful Serum Marker for Diagnosis and Recurrence Detection of Giant Cell Tumor of Bone.The open orthopaedics journal · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Giant cell tumor of bone can be locally aggressive and occasionally can metastasize in the lungs. To identify new markers predictive of aggressive behavior, we analyzed five patients who developed lung metastasis and five who remained disease free for a minimum of 5 years. Using two-dimensional electrophoresis, we detected 28 differentially expressed spots. Fourteen spots were identified using mass spectrometry, including seven up-regulated and seven down-regulated in metastatic samples and classified according to functional categories. We then selected five proteins involved in cell cycle or apoptosis. Thioredoxin peroxidase, allograft inflammatory factor 1, and ubiquitin E2N had more than threefold up-regulation; glutathione peroxidase 1 had 1.9-fold up-regulation; and heat shock protein 27 showed down-regulation in metastatic samples with a very low P value. After validation and analysis of protein levels, evaluation of clinical impact was assessed in a much wider cohort of primary archival specimens. Immunodetection showed a higher frequency of thioredoxin peroxidase, allograft inflammatory factor 1, ubiquitin E2N, and glutathione peroxidase 1 overexpression in primary tumors that developed into lung metastases or that locally relapsed than in the disease-free group, with variable stain intensity and distribution. Kaplan-Meier analysis showed that high expression of glutathione peroxidase 1 was strongly related to local recurrence and metastasis, suggesting that its up-regulation may identify a subset of high-risk patients with giant cell tumor prone to receive diverse clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.